Ukr.Biochem.J. 2015; Volume 87, Issue 1, Jan-Feb, pp. 99-108


Antioxidant properties of cluster rhenium compounds and their influence of erythropoiesis of rats with Guerin carcinoma

Y. S. Voronkova1, S. O. Babiy1, L. V. Ivans’ka2, O. V. Shtemenko3, N. I. Shtemenko1

1Oles Honchar Dnipropetrovsk National University, Ukraine;
2Municipal Institution Dnipropetrovsk Polyprofile Clinical Hospital N 4
of Dnipropetrovsk Region Council, Clinic Diagnostic Laboratory, Ukraine;
3Ukrainian State University of Chemical Technology, Dnipropetrovsk;

Biochemical characteristics of kidneys, peripheral blood and bone marrow of rats in model of tumor growth under introduction of cisplatin and cis-tetrachlorodi-μ-isobutyratodirhenium(III), cis-Re2(i-C3H7COO)2Cl4 (I) have been investigated. It was shown that introduction of I alone and together with cisplatin led to decrease of biochemical markers of oxidation of lipids and proteins in tissue homogenates of the kidneys, change of enzyme activity in the urea and tissue homogenates of the kidneys, by a decrease of filtration function of kidneys. Introduction of nanoliposomal forms of the rhenium cluster compound led to a practically normal morphological picture of bone marrow and increase of the RBC (by 60%) with normalization of hematocrit counts, and decrease of quantities of destructed RBC (3.2 times) in comparison with the tumor-bearing animals. A tentative scheme of influence of cluster rhenium compound on erythropoiesis through regulation of synthesis of erythropoietin in kidneys has been proposed.

Keywords: , , , ,


  1. Shtemenko NI, Berzenina OV, Yegorova DE, Shtemenko AV. Liposomal forms of rhenium cluster compounds: enhancement of biological activity. Chem Biodiversity. 2008;5:1660-1667. CrossRef
  2. Leus I. Superoxide dismutase activity and oxidative stress intensity upon application of rhenium cluster compounds with alkyl ligands as antitumor therapeutics. I. V. Leus: Manuscript. K., 2012. 21 p. (In Ukrainian).
  3. Ivchuk VV, Polishko TN, Golichenko OA, Shtemenko OV, Shtemenko NI. Influence of antitumor system Rhenium-Platinum on biochemical state of the liver. Ukr Biokhim Zhurn. 2011 May-Jun;83(3):76-84. Ukrainian. PubMed
  4. Babiy SO, Loskutova TO, Shtemenko NI. Changes of the state of rat kidneys under guerin carcinoma development and use of cytostatics. Ukr Biokhim Zhurn. 2012 May-Jun;84(3):63-71. Ukrainian. PubMed
  5. Leus IV, Shamelashvili KL, Skorik OD, Tretyak SY, Golichenko OA, Shtemenko OV, Shtemenko NI. Antioxidant and antitumor activity of dirhenium dicarboxylates in animals with Guerin carcinoma. Ukr Biokhim Zhurn. 2012 May-Jun;84(3):72-81. Ukrainian. PubMed
  6. Voronkova Yu S, Skorik OD, Shtemenko NI. Characteristics of the anaemic and hypoglycemia state of blood at the Guerin’s carcinoma growth and application of cisplatin and Rhenium cluster compounds at different forms of introduction. Med. Chem. 2012;14(2):18-25. (In Ukrainian).
  7. Pyrozhkova-Patalah IV. Antioxidant and antitumor activity of cluster Rhenium compounds. I. V. Pyrozhkova-Patalah: Manuscript. Charcov, 2001. 21 p. (In Ukrainian).
  8. Maxwell AP, Lappin TR, Johnston CF, Bridges JM, McGeown MG. Erythropoietin production in kidney tubular cells. Br J Haematol. 1990 Apr;74(4):535-9. PubMed, CrossRef
  9. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979 Jun;95(2):351-8. PubMed, CrossRef
  10. Orechovich VN. The modern methods of biochemistry. M.: Medicine, 1977. 392 p. (In Russian).
  11. Babii SO, D’omshina OO, Trushenko OV, Shtemenko NI. Influence antitumor system rhenium-platinum on the renal function in rats model of toxic nephropath. Visnyk Problem Biol Med. 2010;3:94-101. (In Ukrainian).
  12. Kozenc GI, Makarov VA. Investigation the system of blood in clinic. M.: Triada-X, 1997. 480 p. (In Russian).
  13. Il’inskaya IV. The technique of taking the bone marrow of animals. In Leningrad SRC transfusion of blood. The Topical Issues of Blood Transfusion. 1958;6:306-309. (In Russian).
  14. Lakin GF. Biometry. M.: The higher school, 1990. 352 p. (In Russian).
  15. Rjiba-Touati K, Ayed-Boussema I, Belarbia A, Azzebi A, Achour A, Bacha H. Protective effect of recombinant human erythropoeitin against cisplatin cytotoxicity and genotoxicity in cultured Vero cells. Exp Toxicol Pathol. 2013 Jan;65(1-2):181-7. Epub 2011 Sep 15. PubMed, CrossRef
  16. Pather L. Nephrotoxicity as a cause of acute kidney injury in children. Pediatr. Nephrol. 2007;39:32-47.
  17. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004 Nov;4(11):891-9. Review. PubMed, CrossRef
  18. Vazquez A, Liu J, Zhou Y, Oltvai ZN. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst Biol. 2010 May 6;4:58. PubMed, PubMedCentral, CrossRef
  19. Shtemenko NI, Babiy SA, Chifotides HT, Domasevitch KV, Golichenko AA, Li Z., Paramonova KV, Shtemenko AV, Dunbar KR. Synthesis, X-ray structure, interactions with DNA, remarkable in vivo tumor growth suppression and nephroprotective activity of cis-tetrachloro-dipivalato dirhenium(III). J. Inorg. Chem. 2013;129:127-134. CrossRef
  20. Bilenko O., Rudenko M., Leus I., Babiy S., Skorik O., Shtemenko N. Investigation of glutathione system under inhibition of tumor growth. Visnyk of the Lviv University. Series Biology. 2013;62:68-74. (In Ukranian).
  21. Kim YK, Jung JS, Lee SH, Kim YW. Effects of antioxidants and Ca2+ in cisplatin-induced cell injury in rabbit renal cortical slices. Toxicol Appl Pharmacol. 1997 Oct;146(2):261-9. PubMed, CrossRef
  22. Naziroglu M, Karaoğlu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004 Feb 15;195(2-3):221-30. PubMed, CrossRef
  23. Atessahin A, Yilmaz S, Karahan I, Ceri­basi AO, Karaoglu A. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology. 2005;212:116-123.  CrossRef
  24. Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci. 2005 Mar 18;76(18):2125-35. PubMed, CrossRef
  25. Yüce A, Ateşşahin A, Ceribaşi AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol. 2007 Nov;101(5):345-9. PubMed, CrossRef
  26. Atasayar S, Gürer-Orhan H, Orhan H, Gürel B, Girgin G, Ozgüneş H. Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats. Exp Toxicol Pathol. 2009 Jan;61(1):23-32. PubMed, CrossRef
  27. Graf N, Lippard SJ. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev. 2012 Aug;64(11):993-1004. Review. PubMed, CrossRef
  28. Dicato M, Plawny L, Diederich M. Anemia in cancer. Ann Oncol. 2010 Oct;21 Suppl 7:vii167-72. Review. PubMed, CrossRef
  29. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 1993 Jun;67(6):1171-6. Review. PubMed, PubMedCentral, CrossRef
  30. Yilmaz S, Ates E, Tokyol C, Pehlivan T, Erkasap S, Koken T. The protective effect of erythropoietin on ischaemia/reperfusion injury of liver. HPB (Oxford). 2004;6(3):169-73. PubMed, PubMedCentral, CrossRef
  31. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003 Jun;4(6):889-901. Review. PubMed, CrossRef
  32. Hasserjian RP. Reactive versus neoplastic bone marrow: problems and pitfalls. Arch Pathol Lab Med. 2008 Apr;132(4):587-94. Review. PubMed
  33. Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Müller G, Brune T, Kraemer HP, Mertelsmann R. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol. 1990 Jun;8(6):956-62. PubMed
  34. Kumar A, Singh SM. Effect of cisplatin administration on the proliferation and differentiation of bone marrow cells of tumour-bearing mice. Immunol Cell Biol. 1995 Jun;73(3):220-5. PubMed, CrossRef
  35. Foucar K. Bone Marrow Pathology. American Society Clinical Pathology; 2nd edition, 2001. 704 p.
  36. Lavrova VS, Chernova EN, Karpova GV, Stepovaya EA. Dysregulatory process in blood system during carcinogenesis. Bulletin of Siberia Med. 2006;2:75-83. (In Russian).
  37. Chernova EN. The morphofunctional characteristics of erythron during the growth of transplantable and induced tumors. E. N. Chernova: Manuscript, Tomsk, 1988. 189 p. (In Russian).
  38. Prajda N, Kralovánszky J, Gal F, Kiss F, Kerpel-Fronius S. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow. In Vivo. 1989 Jul-Aug;3(4):267-70. PubMed
  39. Bäck H, Gustavsson A, Eksborg S, Rödjer S. Accidental doxorubicin overdosage. Acta Oncol. 1995;34(4):533-6. PubMed, CrossRef
  40. Lund JE, Toxicologic effects on blood and bone marrow. Schalm’s Veterinary Hematology. 2000;5:44-50.
  41. Gossett K. Anemias associated with drugs and chemicals. Schalm’s Veterinary Hematology. 2000;5:185-189.
  42. Andrews C, Williams T, Turton J. Long-term haematological alterations in female B6C3F1 mice treated with busulphan. Comp Haematol Int. 1998;8:125-138.  CrossRef
  43. Manyan DR, Arimura GK, Yunis AA. Chloramphenicol-induced erythroid suppression and bone marrow ferrochelatase activity in dogs. J Lab Clin Med. 1972 Jan;79(1):137-44. PubMed
  44. Bloom J, Lewis H. Bone marrow as a target organ: an integrated approach to investigate hematopathology in toxicologic evaluations. Toxicol. Pathol. 1990;18:706-707.
  45. Schwerdt G, Freudinger R, Schuster C, Weber F, Thews O, Gekle M. Cisplatin-induced apoptosis is enhanced by hypoxia and by inhibition of mitochondria in renal collecting duct cells. Toxicol Sci. 2005 May;85(1):735-42. PubMed, CrossRef
  46. Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol. 2010 Jul;299(1):F1-13. Epub 2010 May 5. Review. PubMed, PubMedCentral, CrossRef
  47. Koury MJ, Bondurant MC, Graber SE, Sawyer ST. Erythropoietin messenger RNA levels in developing mice and transfer of 125I-erythropoietin by the placenta. J Clin Invest. 1988 Jul;82(1):154-9. PubMed, PubMedCentral, CrossRef
  48. Lundby C. Synthesis, function and possible new avenues for erythropoietin. J Physiol. 2011 Mar 15;589(Pt 6):1249. PubMed, PubMedCentral, CrossRef
  49. Neumcke I, Schneider B, Fandrey J, Pagel H. Effects of pro- and antioxidative compounds on renal production of erythropoietin. Endocrinology. 1999 Feb;140(2):641-5. PubMed, CrossRef
  50. Shtemenko AV, Collery P, Shtemenko NI, Domasevitch KV, Zabitskaya ED, Golichenko AA. Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin. Dalton Trans. 2009 Jul 14;(26):5132-6. Epub 2009 May 8. PubMed , CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.